Finance

Lists
Q3 2026 earnings • released • EPS beat +4.04%
See results
EIKN:NASDAQ
Eikon Therapeutics Inc
$5.98
-0.99%
(-0.060) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EIKN...
Open
$6.06
High
$6.10
Low
$5.58
Mkt. cap
323.91M
Avg. vol.
549.61K
Volume
294.01K
P/E ratio
0.11
52-wk high
$17.40
52-wk low
$5.01
EPS
$53.57
No. of employees
384
Open
$6.06
High
$6.10
Low
$5.58
Mkt. cap
323.91M
Avg. vol.
549.61K
Volume
294.01K
P/E ratio
0.11
52-wk high
$17.40
52-wk low
$5.01
EPS
$53.57
No. of employees
384
News stories
From web sources and news partners
About Eikon Therapeutics Inc
CEO-
Employees384
Founded2019
HeadquartersMillbrae, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteeikontx.com
Analyst ratings
Based on 5 analysts giving stock ratings to EIKN in the past 3 months
Buy
Buy
4
Hold
0
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for EIKN in the last 3 months.
Highest
Current $5.98
$32.00 (+435.12%)
Average
$22.75 (+280.43%)
Lowest
$4.00 (-33.11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Wedbush
Sell
Reiterated
$4.00
-33.1%
11/13/2026
Sara Nik
H.C. Wainwright
Buy
Reiterated
$23.00
+284.6%
11/12/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
-
-
10/26/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$32.00
+435.1%
10/19/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$32.00
+435.1%
08/17/2026
Robert Driscoll
Wedbush
Sell
Maintained
$5.00
-16.4%
05/12/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$26.00
+334.8%
03/02/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$1.59 / -$1.66
+4.04%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
65.23M
70.05M
75.46M
71.83M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.73M
17.29M
17.93M
18.73M
Operating expense
82.96M
87.34M
93.39M
90.55M
Total operating expenses
82.96M
87.34M
93.39M
90.55M
Operating income
-82.96M
-87.34M
-93.39M
-90.55M
Other non operating income
-9.00K
-1.00K
-52.00K
-46.00K
EBT including unusual items
-79.66M
-82.96M
-88.41M
-86.11M
EBT excluding unusual items
-79.45M
-82.96M
-88.41M
-86.11M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-79.66M
-82.96M
-88.41M
-86.11M
Net profit margin
-
-
-
-
Earnings per share
-26.23
-2.46
-1.63
-1.59
Interest and investment income
3.52M
4.38M
5.04M
4.49M
Interest expense
-
-
-
-
Net interest expenses
3.52M
4.38M
5.04M
4.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
-77.57M
-82.12M
-88.26M
-85.42M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps